











A 55-year-old male with coronary
artery disease status post drug-eluting
stents in 2009, maintained on dual
antiplatelet therapy (DAPT) with
clopidogrel 75mg daily and aspirin
(ASA) 325mg daily, and an 80 pack-
year history of tobacco dependence
was referred for evaluation of a right
upper lobe lung nodule. No additional
risk factors for bleeding were identi-
fied. Computed tomography of the
chest showed a 29.0mm spiculated
right upper lobe nodule with right
hilar and paratracheal lymphadenop-
athy. Poor functional status excluded
him from possible curative intent
surgery by previous thoracic surgery
consultation.
The patient underwent staging
endobronchial ultrasound-guided
transbronchial needle aspiration
(EBUS-TBNA) followed by navi-
gation bronchoscopy with biopsy
and fiducial marker placement for
potential radiosurgery. Both ASA
and clopidogrel were held 6 days
before the procedure. One hour
before the procedure, ASA 325mg
was administered out of the concern
for potential elevated risk of peri-
procedural myocardial infarction.
Lymph nodes at stations 4L, 7, 4R,
and 11R (measuring in the shortest
diameter 8, 12, 9, and 11mm,
respectively) were noted by EBUS
without significant vascularity. Three
passes per lymph node were obtained
with a 21-G EBUS-TBNA needle.
Rapid on-site cytologic evaluation
was negative for malignancy. There
was no excessive intraluminal bleed-
ing or hematoma on ultrasound
immediately following the procedure.
The navigational portion of the pro-
cedure was uneventful. The patient
was discharged the same afternoon
with instructions to resume DAPT.
Clopidogrel was restarted ∼4 hours
after the procedure.
On postprocedure day 4, the
patient presented to the emergency
department with acute right-sided
chest pain associated with progressive
dyspnea. Computed tomography
revealed a large right pleural effusion
with layering internal hyperdensity in
apparent communication with a pos-
terior mediastinal fluid collection
(Fig. 1). A 14-Fr chest tube was
placed, draining 1050mL of hemor-
rhagic pleural fluid. The fluid
hematocrit was 20% (systemic 32%),
confirming the diagnosis of hemo-
thorax. Progressive tachycardia and
hypotension developed with 400mL
additional hemorrhagic fluid drained
over the next hour. Four units
of packed red blood cells were trans-
fused emergently; however, the




omy, revealing 1 L of thrombus
in the right hemithorax and a large
posterior mediastinal hematoma.
Intraoperative transesophageal echo-
cardiogram revealed left atrial com-
pression with impaired cardiac
function (Fig. 2). There was no clear
evidence of injury to major cardiac
or vascular structures, but hemor-
rhage appeared to originate in the
subcarinal region. After an unevent-
ful recovery, he was discharged on
postoperative day 5.DOI: 10.1097/LBR.0000000000000589
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DISCUSSION
EBUS-TBNA, shown in multiple
studies to be a safe and cost-
effective means of evaluating
mediastinal and hilar lesions, is
the first procedure of choice for
mediastinal evaluation and
staging in suspected broncho-
genic carcinoma.1,2 Rates of
complications—including bleed-
ing, pneumothorax, and infection
—are low, ranging from 0.14% to
1.44%.1,2 Our case demonstrates a
previously unreported but poten-
tially life-threatening complication
of EBUS-TBNA: delayed major
hemorrhage.
Being the first reported case,
there are some features that war-
rant discussion. Current recom-
mendations suggest holding only
clopidogrel for 5 to 7 days,3,4 while
our patient held both ASA and
clopidogrel due to the unusual
combination of 325mg of ASA
with clopidogrel, which raised
concern for potential bleeding
complications. In addition, our
patient developed clinically evident
bleeding several days post-
procedure, different from prior
studies which focus on periproce-
dural bleeding.5–9 Finally, prior
publications report endobronchial
and intramural bleeding,10,11
whereas our patient had significant
hemorrhage into the mediastinum
and pleura.
One explanation for our
patient’s presentation is the com-
bination of full dose ASA the
morning of the procedure and
clopidogrel ∼4 hours after the
procedure, resulting in prolonged
mediastinal bleeding due to ASA-
induced platelet dysfunction exa-
cerbated by resuming clopidogrel
shortly thereafter. Prior case
series suggest that EBUS-TBNA is
safe in patients taking clopidogrel.
Stather et al5 report 12 patients on
clopidogrel who underwent sam-
pling of 24 lymph node stations (2
to 4 passes per station) with no
cases of severe bleeding. These
findings were replicated by Meena
et al6 in 28 patients on clopidogrel
undergoing EBUS-TBNA and 55
patients undergoing EUS-TBNA.
In contrast, Karnyski et al10
describe a case of hemorrhage
from a right lower lobe mass
after EBUS-TBNA requiring tem-
porary placement of an endo-
bronchial balloon to achieve
hemostasis. Furthermore, a pro-
spective study by Ernst et al12 of
604 patients undergoing trans-
bronchial biopsy was stopped early
due to an 89% rate of major
hemorrhage in patients continuing
clopidogrel alone and 100% in
FIGURE 1. A, Computed tomography scan day of presentation with mediastinal hematoma (black asterisk) and right
hemothorax (white asterisk). B, Preprocedural computed tomography.
FIGURE 2. Mediastinal hematoma (arrow) compressing left atrium (white
asterisk) on intraoperative transesophageal echocardiogram.
should identify patients in whom
clopidogrel can be safely stopped
and determine the optimal time to
resume DAPT. Clinicians should
have a high index of suspicion for
postprocedural complications in
patients restarting DAPT after
EBUS-TBNA who present up to
several days later with unexplained
chest pain or respiratory and/or
hemodynamic compromise.
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those continuing DAPT, leading to 
the recommendation for stopping 
clopidogrel 5 to 7 days before 
transbronchial biopsy and sug-
gesting that aspirin exacerbates the 
bleeding risk of clopidogrel. 
Regarding the optimal time to 
reinitiate DAPT, expert opinion 
suggests reinitiation 12 to 24 hours 
postprocedure; however, there are 
no published data evaluating this 
question.3,4
A second possible explanation 
is unrecognized transvascular or 
atrial passage of the needle during 
mediastinal lymph node biopsy. 
Published case series suggest low 
risk of bleeding from EBUS-
TBNA in the setting of trans-
vascular needle aspiration7–9; 
however, the technique is not 
without risk—as shown by 
Botana-Rial et al,11 who report the 
development of intramural hema-
toma after EBUS-TBNA pulmo-
nary arterial puncture. The authors 
note that, had they not seen 
the hematoma on immediate 
postpuncture ultrasound, no fur-
ther investigation would have been 
performed. Thus, asymptomatic 
bleeding may be underrecognized 
due to lack of routine radiographic 
follow-up. In addition, this proce-
dure was performed in a training 
setting, raising the possibility of 
inadvertent vascular puncture or 
laceration due to operator inex-
perience. Although the primary 
operator in this case was a sub-
specialty trainee with 249 recorded 
EBUS-TBNA cases, Stather et al13 
demonstrate that skill with EBUS-
TBNA continues to improve even 
after 200 cases.
CONCLUSIONS
EBUS-TBNA is a safe, effective, 
and minimally invasive means of 
sampling mediastinal and hilar 
lesions. Although complications 
are rare, special consideration 
should be taken in patients requir-
ing DAPT. The proceduralist
